17α-Hydroxy Progesterone for sale

17-Hydroxyprogesterone (17OHP) is not the same compound as 17-hydroxyprogesterone caproate (17OHPC), the latter being the caproic acid of 17-Hydroxyprogesterone that was first clinically introduced as an injectable version of the steroid under the name of Delalutin in 1956.
The use of 17-hydroxyprogesterone caproate in pregnancy to prevent preterm birth has a long history. A 2006 Cochrane Review concluded "...important maternal and infant outcomes have been poorly reported to date... information regarding the potential harms of progesterone therapy to prevent preterm birth is limited".There was a similar conclusion from a review by Marc Keirse. Three clinical studies of 250 mg/week of i.m. 17-hydroxyprogesterone caproate showed a trend for an increase in pregnancy loss due to miscarriage compared to placebo.There had been speculation that the castor oil in some 17-hydroxyprogesterone caproate formulations may not be beneficial for pregnancy.In contrast, a large NIH study in 2003 looked at the effect of 17OHPC injections in women at risk for repeat premature birth and found that the treated group experienced premature birth in 37% versus 55% in the controls.A follow-up study of the offspring showed no evidence that 17OHPC affected the children in the first years of life.Based on these NIH data, 17 OHPC was approved by the FDA in 2011 as a drug to reduce the risk of premature birth in selected patients at risk. (v.i.)
17-hydroxyprogesterone caproate is a category B drug according to the FDA.
read more: http://www.steroid-hormones.com/